Filgotinib hits more RA endpoints

Gilead and Galapagos took a step closer to submitting regulatory applications for filgotinib to treat rheumatoid arthritis after the partners reported positive data from the two remaining Phase III trials of the oral Janus kinase-1 (JAK-1) inhibitor.

On FINCH 1’s primary

Read the full 409 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE